FDAnews Device Daily Bulletin

ENDOSENSE COMPLETES CHF 26 MILLION (USD 20 MILLION) FUNDRAISING BACKED BY 3I AND NEOMED

Nov. 22, 2005
A A

Endosense, an emerging cardiovascular device company, recently announced the closing of a CHF 26 million (USD 20 million) financing with 3i and NeoMed. Endosense, set up in 2003, is developing a Force Sensor ablation catheter for use in the field of cardiac arrhythmia. Eric Le Royer, newly appointed CEO and previously Vice President of Marketing at Guidant, will join CTO Giovanni Leo on the board, together with Dina Chaya of 3i, that led the financing, and Claudio Nessi of NeoMed.

EndoSense (http://www.endosense.com/site/news.htm)